EMvision Medical Devices Ltd. (AU:EMV)
ASX:EMV
Want to see AU:EMV full AI Analyst Report?
Top Page
EMvision Medical Devices Ltd.
(Sydney:EMV)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$2.00
▲(12.99% Upside)
Action:Reiterated
Date:10/29/25
The overall stock score of 44 reflects significant financial challenges, including declining revenues and persistent losses. The technical analysis indicates weak momentum, and the valuation is unattractive due to a negative P/E ratio and no dividend yield. These factors collectively suggest a cautious outlook for the stock.
Positive Factors
Point-of-care brain imaging
EMvision’s focus on a portable electromagnetic brain-imaging platform targets a durable, structural need: faster stroke and TBI detection at bedside and in pre-hospital settings. If commercialized, this capability addresses long-term clinical workflow gaps and supports sustained product demand in emergency care.
Negative Factors
Steep revenue decline
A >30% revenue contraction indicates weakening commercial traction or reduced trial/commercial activity. This undermines scale economics, hampers ability to absorb fixed R&D and G&A costs, and materially raises the risk that further external funding or operational restructuring will be required within a 2-6 month horizon.
Read all positive and negative factors
Positive Factors
Negative Factors
Point-of-care brain imaging
EMvision’s focus on a portable electromagnetic brain-imaging platform targets a durable, structural need: faster stroke and TBI detection at bedside and in pre-hospital settings. If commercialized, this capability addresses long-term clinical workflow gaps and supports sustained product demand in emergency care.
Read all positive factors
EMvision Medical Devices Ltd. (EMV) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$158.95M
Dividend YieldN/A
Average Volume (3M)120.98K
Price to Earnings (P/E)―
Beta (1Y)0.60
Revenue GrowthN/A
EPS Growth-62.15%
CountryAU
Employees46
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.11
Shares Outstanding92,955,560
10 Day Avg. Volume127,185
30 Day Avg. Volume120,982
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)16.01
Price to Sales (P/S)29.42
P/FCF Ratio-18.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.15Price Target Upside77.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.1
Revenue Forecast (FY)AU$5.50M
EMvision Medical Devices Ltd. Business Overview & Revenue Model
Company Description
EMvision Medical Devices Limited, a medical device company, engages in the research, development, and commercialization of imaging and diagnostic technology products. It develops a portable brain scanner for stroke diagnosis, monitoring, as well a...
How the Company Makes Money
null...
EMvision Medical Devices Ltd. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.56M | 5.05M | 11.22M | 6.97M | 4.36M | 1.70M |
| Gross Profit | 1.35M | 5.05M | 11.22M | 6.63M | 4.12M | 1.58M |
| EBITDA | -13.27M | -8.71M | -8.35M | -5.99M | -7.84M | -9.56M |
| Net Income | -10.20M | -9.81M | -2.73M | -3.87M | -6.11M | -8.40M |
Balance Sheet | ||||||
| Total Assets | 24.94M | 15.57M | 23.97M | 11.52M | 8.51M | 10.77M |
| Cash, Cash Equivalents and Short-Term Investments | 17.56M | 10.53M | 18.67M | 9.97M | 6.80M | 9.69M |
| Total Debt | 4.02M | 3.53M | 2.90M | 3.04M | 737.86K | 213.17K |
| Total Liabilities | 5.20M | 6.29M | 5.46M | 6.40M | 1.43M | 720.01K |
| Stockholders Equity | 19.74M | 9.28M | 18.52M | 5.12M | 7.08M | 10.05M |
Cash Flow | ||||||
| Free Cash Flow | -9.02M | -7.89M | -6.29M | 646.86K | -3.97M | -4.62M |
| Operating Cash Flow | -8.94M | -7.84M | -5.99M | 834.15K | -3.78M | -4.49M |
| Investing Cash Flow | -78.32K | -50.37K | -302.41K | -187.29K | -191.12K | -127.25K |
| Financing Cash Flow | 12.96M | -258.34K | 15.00M | 2.52M | 1.08M | 8.90M |
EMvision Medical Devices Ltd. Technical Analysis
Negative
1.77
Price Trends
1.71
Negative
1.72
Negative
1.81
Negative
Market Momentum
-0.02
Positive
45.25
Neutral
15.96
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EMV, the sentiment is Negative. The current price of 1.77 is above the 20-day moving average (MA) of 1.74, above the 50-day MA of 1.71, and below the 200-day MA of 1.81, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 45.25 is Neutral, neither overbought nor oversold. The STOCH value of 15.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EMV.
EMvision Medical Devices Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | AU$233.48M | 65.27 | 4.20% | ― | 19.23% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$18.71M | -0.58 | -165.13% | ― | 23.30% | -14.29% | |
44 Neutral | AU$158.95M | -14.77 | -70.29% | ― | ― | -62.15% | |
44 Neutral | AU$83.20M | -4.02 | -54.48% | ― | 17.24% | -20.00% | |
42 Neutral | AU$52.94M | 467.33 | 0.48% | ― | 24.45% | ― | |
41 Neutral | AU$2.26B | -12.24 | -890.76% | ― | -0.80% | -249.48% |
* Healthcare Sector Average
AU:EMV
EMvision Medical Devices Ltd.
1.69
-0.02
-1.17%
AU:CMP
Compumedics Limited
0.26
-0.03
-8.93%
AU:IPD
Impedimed Limited
0.01
-0.02
-58.82%
AU:CYC
Cyclopharm Limited
0.63
-0.45
-41.67%
AU:ARX
Aroa Biosurgery Ltd
0.66
0.14
26.92%
AU:4DX
4DMedical Ltd
3.92
3.60
1125.00%
EMvision Medical Devices Ltd. Corporate Events
EMVision issues new shares under employee incentive plan with cleansing notice
May 11, 2026
EMVision Medical Devices has issued 16,957 fully paid ordinary shares following the exercise of an equal number of unlisted performance rights under its Employee Incentive Plan. The company confirmed that these shares qualify for on-sale without a...
EMvision Lists New Tranche of Ordinary Shares on ASX
May 11, 2026
EMvision Medical Devices Ltd., an ASX-listed medtech company, has issued a small tranche of 16,957 fully paid ordinary shares. The new securities have been approved for quotation on the ASX, modestly increasing the company’s listed share cap...
EMVision expands pivotal emu brain scanner trial to include acute ischaemia detection
May 10, 2026
EMVision is expanding the scope of its pivotal validation trial for the emu brain scanner to include acute ischaemia detection alongside haemorrhage detection, leveraging progress from a parallel Continuous Innovation study. This simultaneous vali...
EMvision Director Increases Stake with On-Market Share Purchase
Apr 23, 2026
EMvision Medical Devices has reported a change in director Carmel Monaghan’s holdings, following an on-market purchase of additional equity in the company. Monaghan acquired 10,000 ordinary shares on 22 April 2026 for a total consideration o...
EMVision Advances Pivotal Brain Scanner Trial as Cash Runway Strengthens
Apr 12, 2026
EMVision reported solid progress in its pivotal validation trial for the emu brain scanner, with eight major hospitals in the U.S. and Australia now actively recruiting stroke patients and no device-related adverse events recorded. Growing interna...
EMvision Issues 60,000 Unquoted Performance Rights Under Employee Incentive Scheme
Apr 10, 2026
EMvision Medical Devices Ltd. has notified the market of the issue of 60,000 unquoted performance rights under its employee incentive scheme, with these rights expiring on April 10, 2031. The new performance rights, not intended to be quoted on th...
S&P Dow Jones Revises March 2026 All Ordinaries Rebalance
Mar 10, 2026
SP Dow Jones Indices has updated its March 2026 quarterly rebalance for the All Ordinaries, reversing the previously announced inclusion of African Gold Limited and the removal of American Rare Earths Limited. The index will instead see a range of...
S&P Dow Jones Indices Unveils March 2026 S&P/ASX Rebalance
Mar 6, 2026
SP Dow Jones Indices has announced changes to its SP/ASX equity benchmarks following the March quarterly review, reshaping the composition of the main Australian indices across the large-, mid-, and small-cap segments. The rebalance reflects shift...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.